Sportradar Announces Preliminary First Quarter 2025 Financial Results 23-04-2025, 04:05

Freshworks Appoints Johanna Jackman as Chief People Officer 28-08-2023, 19:00

Io Therapeutics, Inc., presented data from studies of IRX4204, the company’s phase II clinical development stage, highly selective third generation RXR nuclear receptor agonist compound, supporting its potential use for prevention and treatment of normal 10-07-2024, 07:00